Blockchain Registration Transaction Record

Okogen Inc. Submits Regulatory Application for Phase IIb Clinical Trial in India

Okogen Inc. announces regulatory submission for Phase IIb clinical trial, appoints Dr. Hollander as CMO. The Emerald Study aims to evaluate triple-combination eyedrop for bacterial and viral conjunctivitis.

Okogen Inc. Submits Regulatory Application for Phase IIb Clinical Trial in India

This news matters as Okogen's innovative approach to treating acute infectious conjunctivitis could potentially revolutionize the ophthalmology field. The appointment of Dr. Hollander and the upcoming clinical trial signify a significant step towards addressing the unmet needs of patients suffering from this condition.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0xef734599a2f01545652f41edeed96610d2290f3e819d77ce6732885fcf8a9f12
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintjadefXfH-020b3899ee90ebb8d1caa2e2a4c34077